Comparator: Estrace 0.5 mg + Comparator: Estrace 2 mg + Comparator: Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal Symptoms
Conditions
Postmenopausal Symptoms
Trial Timeline
Dec 1, 2008 → May 1, 2009
NCT ID
NCT00820664About Comparator: Estrace 0.5 mg + Comparator: Estrace 2 mg + Comparator: Placebo
Comparator: Estrace 0.5 mg + Comparator: Estrace 2 mg + Comparator: Placebo is a phase 1 stage product being developed by Merck for Postmenopausal Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00820664. Target conditions include Postmenopausal Symptoms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00820664 | Phase 1 | Completed |
Competing Products
20 competing products in Postmenopausal Symptoms